Key Points
- Director Abbas Hussain sold 5,682 Moderna shares at an average of $46.63 for $264,951.66 under a pre-arranged Rule 10b5-1 plan, cutting his holdings by 32% to 12,066 shares.
- Moderna reported Q results with EPS of ($3.40), missing estimates by $0.38, while revenue came in at $389 million—up 260.2% year-over-year and above expectations.
- Analysts are mixed: the stock trades near $47 with a market cap of about $18.7B, and the consensus rating is "Reduce" with an average target of $35.73.
Moderna, Inc. (NASDAQ:MRNA - Get Free Report) Director Abbas Hussain sold 5,682 shares of the company's stock in a transaction on Friday, May 1st. The shares were sold at an average price of $46.63, for a total transaction of $264,951.66. Following the completion of the sale, the director directly owned 12,066 shares in the company, valued at $562,637.58. This represents a 32.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Moderna Trading Up 4.3%
MRNA opened at $47.30 on Tuesday. The stock has a market capitalization of $18.68 billion, a PE ratio of -5.80 and a beta of 1.05. The firm's fifty day moving average price is $51.84 and its 200 day moving average price is $39.47. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.41 and a quick ratio of 2.35. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $59.55.
Moderna (NASDAQ:MRNA - Get Free Report) last issued its earnings results on Friday, May 1st. The company reported ($3.40) earnings per share for the quarter, missing analysts' consensus estimates of ($3.02) by ($0.38). The business had revenue of $389.00 million for the quarter, compared to analyst estimates of $236.37 million. Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The firm's revenue for the quarter was up 260.2% on a year-over-year basis. During the same period last year, the company posted ($2.52) earnings per share. As a group, research analysts expect that Moderna, Inc. will post -8 EPS for the current fiscal year.
Analysts Set New Price Targets
MRNA has been the topic of a number of research reports. BMO Capital Markets raised shares of Moderna from a "market perform" rating to a "buy" rating in a report on Monday, January 12th. Leerink Partners reissued an "underperform" rating on shares of Moderna in a report on Friday, January 30th. UBS Group increased their target price on shares of Moderna from $36.00 to $45.00 and gave the stock a "neutral" rating in a report on Monday. Jefferies Financial Group set a $37.00 target price on shares of Moderna and gave the stock a "hold" rating in a report on Tuesday, March 3rd. Finally, Royal Bank Of Canada increased their target price on shares of Moderna from $35.00 to $38.00 and gave the stock a "sector perform" rating in a report on Monday. Two equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and five have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Reduce" and an average target price of $35.73.
Check Out Our Latest Report on Moderna
Hedge Funds Weigh In On Moderna
Institutional investors and hedge funds have recently bought and sold shares of the stock. MUFG Securities EMEA plc bought a new position in Moderna in the 2nd quarter valued at about $28,000. Flagship Harbor Advisors LLC bought a new position in Moderna in the 4th quarter valued at about $31,000. Canton Hathaway LLC bought a new position in Moderna in the 1st quarter valued at about $31,000. Ameriflex Group Inc. grew its position in Moderna by 3,775.0% in the 3rd quarter. Ameriflex Group Inc. now owns 1,240 shares of the company's stock valued at $32,000 after buying an additional 1,208 shares in the last quarter. Finally, Cromwell Holdings LLC grew its position in Moderna by 39.7% in the 4th quarter. Cromwell Holdings LLC now owns 1,200 shares of the company's stock valued at $35,000 after buying an additional 341 shares in the last quarter. Institutional investors own 75.33% of the company's stock.
About Moderna
(
Get Free Report)
Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company's platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.
Moderna's flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
